1	Frequent shedding of multi-drug resistant pneumococci among adults living with
2	HIV on suppressive antiretroviral therapy in Malawi
3	
4	Lusako Sibale ^{1,2+} , Joseph Phiri ^{1,2+} , Ndaona Mitole ¹ , Newton Kalata ¹ , Tinashe Nyazika ² ,
5	Alice Kalirani ¹ , Mercy Khwiya ¹ , Gift Sagawa ¹ , Deus Thindwa ¹ , Todd D Swarthout ³ , Neil
6	French ⁴ , Ken Malisita ⁵ , Arox Kamng'ona ⁶ , Daniela M Ferreira ^{2,7} , Robert S. Heyderman ³ ,
7	Brenda A. Kwambana-Adams ^{1,2,3} , Kondwani Jambo ^{1,2*} .
8	
9	1. Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi
10	2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool,
11	UK
12	3. NIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection
13	and Immunity, University College London, WC1E 6JF, London, UK
14	4. Institute of Infection Veterinary & Ecological Science, University of Liverpool, L69
15	3GE, Liverpool, UK
16	5. Lighthouse-Queens Elizabeth Hospital and Gateway Health Centre, Blantyre,
17	Malawi
18	6. School of Life Science and Allied Health Professions, Kamuzu University of Health
19	Sciences, Blantyre, Malawi
20	7. Oxford Vaccine Group, University of Oxford, Oxford, UK
21	
22	*Corresponding author
23	Email: Kondwani.Jambo@lstmed.ac.uk or kjambo@mlw.mw (KCJ)
24	
25	+ Contributed equally to this manuscript
26	
27	Running title: PLHIV shed multi-drug resistant pneumococci
28	Keywords: HIV, ART, Streptococcus pneumoniae, carriage, AMR
29	Were never was a should not be used to guide clinical practice.

30 Abstract

People living with human immunodeficiency virus (PLHIV) on antiretroviral therapy (ART) are reported to have three times higher carriage of *Streptococcus pneumoniae* than their HIV-uninfected counterparts in point prevalence studies. Using a longitudinal cohort study design, we assessed pneumococcal carriage density, shedding and antibiotic resistance profiles, as well as nasal mucosal immunity, in otherwise healthy PLHIV on ART for at least one year, compared to HIV-uninfected participants in Malawi. Pneumococcal carriage density was higher among PLHIV compared to HIV-uninfected participants. Moreover, PLHIV were twice more likely to shed pneumococci than HIV-uninfected participants. In PLHIV, aerosol shed pneumococci were more often multi-drug resistant (MDR) than nasopharyngeal carried isolates recovered from the same individual. Consistent with high shedding, PLHIV exhibited heightened neutrophil-mediated nasal mucosa inflammation. We propose that PLHIV should be considered in intervention strategies, such as vaccination, as they could be an important reservoir for transmission of MDR S. pneumoniae. Word count: 149 words

59 Introduction

Streptococcus pneumoniae has at least 100 distinct serotypes ^{1, 2} and is a common 60 61 coloniser of the human nasopharynx. Pneumococcal carriage is a prerequisite for lifethreatening invasive pneumococcal disease (IPD) including pneumonia, meningitis, 62 and bacteraemia³, and is critical for transmission⁴. In high- and middle-income 63 countries, infant pneumococcal conjugate vaccine (PCV) programmes have resulted 64 65 in a significant reduction in pneumococcal carriage and IPD in both vaccinated children (direct protection) and unvaccinated older children and adults (indirect 66 protection) ^{5, 6, 7, 8}. However, in low-income countries such as Malawi, where the 13-67 valent PCV (PCV13) was introduced into the infant immunisation programme in 2011, 68 there is limited indirect protection among unvaccinated older children and adults 69 70 despite evidence of substantial direct protection against IPD among vaccinated children⁹. 71

72

Moreover, pneumococcal carriage prevalence has been reported to be over two-fold
higher in PLHIV on antiretroviral therapy (ART) (40-60%) than in those HIVuninfected (8-15%) or ART-naïve PLHIV (18-25%) ^{10, 11}. Residual carriage of all PCV13
serotypes (VTs) among Malawian adults living with HIV on ART has remained
relatively high ^{7, 11}, with low socioeconomic status having been shown to exacerbate
overall carriage prevalence¹².

79

Emergence of pneumococcal antimicrobial resistance (AMR) is associated with 80 carriage and antibiotic usage ^{13, 14, 15}. *S. pneumoniae* is among the priority bacterial 81 pathogens due to its increased resistance to penicillin according to World Health 82 Organisation (WHO) Global Antimicrobial Resistance and Use Surveillance System 83 (GLASS) ¹⁶. It has been shown that PLHIV are more likely to take antibiotics, including 84 cotrimoxazole prophylaxis to prevent opportunistic bacterial infections^{17, 18}. 85 86 Moreover, PLHIV are also at increased risk of disease caused by respiratory viruses compared to the general population^{19, 20}. Common viral co-infections ^{21, 22, 23}, 87

including Respiratory Syncytial Virus (RSV) and Influenza²⁴, have been shown to 88 promote high pneumococcal carriage density that in turn drives increased bacterial 89 shedding ^{21, 25, 26}, a surrogate for transmission potential ^{27, 28}. Furthermore, high 90 pneumococcal carriage density has been shown to associate with invasive 91 pneumococcal disease ^{29, 30}. Together, this may suggest that in addition to being at 92 increased risk of invasive pneumococcal disease, PLHIV could be an 93 94 underappreciated reservoir driving transmission of antimicrobial resistant 95 pneumococci in the community, calling for an in-depth evaluation of this population. 96

97 Using a longitudinal cohort study, we investigated pneumococcal carriage density

98 and shedding, as well as nasal immunity, in otherwise healthy PLHIV on ART for more

than one year and HIV-uninfected participants. We show that PLHIV exhibit higher

100 density pneumococcal carriage and more commonly shed antimicrobial resistant

101 pneumococci. These findings have broader implications in the development of

102 interventions to curb AMR pneumococcal disease and transmission.

103

104 Results

105 *Clinical and demographic characteristics*

106Between July 2019 and August 2021, we screened 512 adults among whom 28%

107 (144/512) had confirmed pneumococcal carriage and thus eligible for recruitment

108 (Fig. 1). Of these, 37.5% (54/144) were HIV-uninfected and 62.5% (90/144) were

109 PLHIV on ART for more than 1 year (median 5.5 years [IQR 2.8-10.1]) (Table S1). Due

to Coronavirus disease (COVID-19) pandemic restrictions, 37.5% (54/144) did not

111 complete the study follow-up period of 5 months (Fig. 1). Therefore, the final analysis

is restricted to the 35 HIV-uninfected participants and 55 PLHIV that completed the 5

- 113 months follow-up period. PLHIV, compared to HIV-uninfected participants were
- 114 older, with 44% (24/55) and 20% (7/35) >36 years old, respectively (p=0.049).
- 115 Likewise, compared to HIV-uninfected participants, PLHIV had a lower socioeconomic
- status as measured by asset ownership index ¹² (median 4 [IQR 2.0-5.0] vs. 6 [3.5-

7.50], p=0.005), and a lower CD4 count (median 514 cells/µl [IQR 652-927] vs. 760
cells/µl [IQR [332-750], p<0.001) (Table 1).

119

120 Higher NVT carriage positivity in PLHIV than HIV-uninfected participants

Overall (VT + non-VT [NVT]) pernasal swab pneumococcal positivity was higher 121 122 among PLHIV compared to HIV-uninfected participants (72% [95% CI 68.2-76.2] vs. 123 59% [53.7–64.8] p<0.001) (Fig. 2a). Furthermore, NVT pernasal swab pneumococcal positivity was higher in PLHIV (55.5% [51.2–59.7] vs. 44.9% [39.6–50.2], p=0.002) (Fig. 124 2b). In contrast, VT pernasal swab pneumococcal positivity was similar between 125 PLHIV and HIV-uninfected participants: 19.6% [16.4-23.2] and 18.6% [14.6-23.0], 126 p=0.5777 (Fig. 2a). The dominant VT carriage isolates among both PLHIV, and HIV-127 128 uninfected participants were serotype 3 (49.1% and 43.1%) and serotype 19F (19.4%) and 29.2%) respectively (Fig. 2c). Using a multivariable logistic regression model 129 (adjusting for age, gender, season, socioeconomic status and HIV status), showed 130 that PLHIV were more likely to carry NVT than HIV-uninfected participants (adjusted 131 odds ratio (aOR) 1.4, (95% CI 1.1-1.9, p=0.015)) (Table S2a). In contrast, the likelihood 132 of having VT carriage was similar between PLHIV and HIV-uninfected participants 133 134 (aOR 1.0, (95% CI 0.7-1.5, p>0.9) (Table S2b). Together, these data show that high 135 pneumococcal carriage prevalence in PLHIV is mostly driven by NVT, but also 136 highlight high residual VT carriage of serotype 3 and 19F in both PLHIV and HIVuninfected participants. 137

138

139 *Higher density pneumococcal carriage in PLHIV than HIV-uninfected participants*

140 The overall median pneumococcal carriage density was higher among PLHIV

141 (40,738.03CFU/ml [95% CI 16218.1-104712.9] vs. 10,000.00CFU/ml [4466.84-

22908.68], p<0.001) (Fig. 3). In a multivariable logistic regression model (adjusting for
sex, age, carriage density, season, and socioeconomic status), PLHIV were more likely

to harbour higher density carriage than HIV-uninfected participants (aOR 1.6, 1.1-2.5,

p=0.027) (Table 2). Collectively, these findings show high propensity for high-densitycarriage in PLHIV.

147

148 Higher proportion of pneumococcal shedding in PLHIV than HIV-uninfected

149 participants

150 Considering the high-density carriage in PLHIV, we sought to determine whether 151 they were also more likely to shed pneumococci than HIV-uninfected participants. The overall proportion of adults shedding pneumococci using either sampling 152 technique was significantly higher among PLHIV than HIV-uninfected participants 153 (57.6% [95% CI 48.4-66.4] vs. 27.3% [18.3-45.4], p<0.001) (Fig. 3a). Further analysis 154 revealed that NVT were shed more frequently in PLHIV than HIV-uninfected 155 participants (31.6% [25.9-37.8] vs. 11.2% [5.7-19.2], p<0.001) (Fig. 3b). However, VT 156 shedding was similar between PLHIV on ART and HIV-uninfected participants (6% 157 [3.4-9.7] vs. 5.1% [1.7-11.5], p=0.946) (Fig. 3b). Among the shed VT isolates, serotype 158 3 (73.3% and 40%) and serotype 19F (13.3% and 60%) were dominant among both 159 the PLHIV and HIV-uninfected participants, respectively (Fig. 3c). Moreover, the 160 overall proportion of adults shedding pneumococci were significantly higher in both 161 162 the mechanical (40.3% [95% CI 31.6-49.5] vs. 18.4% [8.8-32], p=0.010) and aerosol (36% [95% CI 27.6-45.1] vs. 14.3% [95% CI 5.9-27.2], p=0.009) samples in PLHIV than 163 164 HIV-uninfected participants (Fig 3d-e).

165

To identify factors influencing pneumococcal shedding, we performed a multivariable 166 logistic regression analysis that included age, gender, socioeconomic status, season, 167 pneumococcal carriage density, and HIV status. HIV status and pneumococcal 168 carriage density were significantly associated with pneumococcal shedding (Table 3). 169 Specifically, PLHIV were twice more likely to shed any pneumococci than HIV-170 171 uninfected participants (aOR 2.4, 95% CI 1.04-5.7, p=0.039), while individuals with 172 high-density pneumococcal carriage, irrespective of HIV status, were greater than 173 three times more likely to shed any pneumococci than those with low-density

carriage (aOR 3.37, 1.56-7.29, p=0.002) (Table 3). Together, these findings show that
high proclivity for pneumococcal shedding in PLHIV, and in individuals with high
density carriage (irrespective of HIV status).

177

178 PLHIV shed antimicrobial resistant pneumococci

179 Next, we sought to assess the antimicrobial susceptibility profile of the carried and 180 shed isolates from PLHIV and HIV-uninfected participants. Overall, the antimicrobial susceptibility profile of nasopharyngeal carriage isolates was similar between PLHIV 181 compared and HIV-uninfected participants (Table 5). However, the proportion of co-182 trimoxazole resistant isolates was significantly higher in PLHIV (98% [95% CI 88%-183 100%] vs. 76% [58%-89%], p=0.002) (Table 4). The overall proportion of non-184 185 susceptible tetracycline (Tet), benzylpenicillin (PenG), as well as multi-drug resistant isolates were significantly higher in aerosol shed isolates compared to 186 nasopharyngeal carriage isolates in PLHIV for samples collected from the same 187 individual (Tet, 61% [95% CI 46%-75%] vs. 26% [14%-41%], p<0.001; PenG, 61% 188 [46%-75%] vs. 32% [19%-48%], p=0.010; MDR, 64% [48%-77%] vs. 30% [CI 17%-189 45%], p=0.001) (Table 5). In contrast, the AMR profile of mechanical shed isolates 190 191 were similar to the nasopharyngeal carriage isolates (Table 6). Among HIV-uninfected participants, no differences were observed in the antimicrobial susceptibility profile 192 193 between shed and carriage isolates, irrespective of the shedding route (Table S3). Together, these data show that PLHIV shed multi-drug resistant pneumococci, 194 especially via the aerosol route. 195

196

197 PLHIV exhibit neutrophil-mediated inflammation in the nasal mucosa

Lastly, we sought to determine whether PLHIV have a more inflamed nasal mucosa
than HIV-uninfected adults, as inflammation has been shown to play a significant
role in pneumococcal shedding ^{31, 32, 33}. To do this, we recruited PLHIV on ART for
more than 1 year, and age- and gender-matched HIV-uninfected adult controls,
irrespective of pneumococcal carriage status, from whom nasal cells and nasal lining

203 fluid samples were collected weekly for 5 weeks (Fig. S1). Using flow cytometry-204 based immunophenotyping, we characterised the immune cell composition in the 205 nasal mucosa, a representative gating strategy is shown in Fig 5a. The abundance of CD14⁺ monocytes (median ratio 0.01 [95% CI 0.001-0.011] vs 0.01 [95% CI 0-0.014], 206 p=0.55) and CD3⁺ T cells (median ratio 0.04 [95% CI 0.01-0.07] vs 0.05 [95% CI 0.02-207 208 0.08], p=0.66) was similar between the two study groups (Fig 5b-c). In contrast, the 209 abundance of neutrophils (median ratio 0.30 [95% CI 0.17-0.43] vs. 0.17 [95% CI 0.06-0.28], p=0.018) was higher in PLHIV than HIV-uninfected participants (Fig 5d). 210 211 To get further understanding of the phenotype of neutrophils, we measured the 212

213 expression of CD62L, which is down regulated during neutrophil activation ^{34, 35}.

214 Neutrophils from PLHIV had lower expression of CD62L than those from HIV-

uninfected participants (Median fluorescent intensity (MFI) 310 [95% CI 264-356] vs.

216 399 [95% CI 345-453], p=0.017) (Fig 5e). Furthermore, PLHIV had higher

217 concentrations of neutrophil pro-inflammatory markers in their nasal lining fluid

including neutrophil extracellular traps (NETs) (3.9 ng/ml [95% CI 0-31.7] vs 1.2 ng/ml

219 [95% CI 0-2.76], p=0.042) and myeloperoxidase (MPO) (393500 pg/ml [95% CI

220 311066-475934] vs 43425 pg/ml [95% Cl 2008-84842], p=0.066), compared to HIV-

221 uninfected participants (Fig 5f-g). Together, these findings show heightened

222 inflammation in the nasal mucosa of PLHIV.

223

224 Discussion

We assessed pneumococcal carriage dynamics in otherwise healthy PLHIV on ART for
more than 1 year compared to HIV-uninfected adults. We found that PLHIV had
high-density pneumococcal carriage and shed antimicrobial resistant *S. pneumoniae*.
Moreover, PLHIV exhibited heightened neutrophil-associated inflammation in the
nasal mucosa. These data highlight this vulnerable HIV-affected population as a
potentially important reservoir for transmission of antimicrobial resistant
pneumococci.

232

233 It is postulated that pneumococcal transmission is primarily through respiratory droplets ³⁶ but direct contact through hands as a vehicle has also been implicated ^{27,} 234 ²⁸. Consistent with this, we observed pneumococcal shedding in adults through nose 235 poking and coughing. Unlike isolates obtained from the nose poking samples 236 237 (nasopharyngeal niche), aerosol shed *S. pneumoniae* (likely from the oropharyngeal 238 niche) from PLHIV were more frequently penicillin-resistant and multidrug-resistant. Streptococcus mitis and Streptococcus oralis, commensals of the human oropharynx, 239 have been implicated as a potential source of antibiotic resistance genes for S. 240 pneumoniae^{37, 38, 39, 40}, through horizontal gene transfer (HGT) of penicillin-binding 241 protein (*pbp*) genes that drive emergence of β -lactam resistance ^{41, 42}. An analysis of 242 243 publicly available pneumococcal genomes has highlighted that *S. mitis* as a more frequent donor of genetically diverse *pbp* gene fragments to *S*. 244 pneumoniae compared with *S. oralis*, with horizontal acquisition mostly confined to 245 pneumococcal serotypes associated with prolonged nasopharyngeal carriage 246 duration ⁴⁰. These findings suggest that proximity between *S. pneumoniae* and other 247 closely-related streptococci species harboring antibiotic resistance genes facilitates 248 their transfer to pneumococci, and this could in part explain the predominance of 249 250 penicillin-resistant pneumococci in the aerosol shed isolates. 251

On the other hand, it has been recently shown that there is an elevated risk of both 252 the acquisition and persistent carriage of multi-drug resistant pneumococci following 253 antimicrobial treatment ⁴³. The mechanism of persistence of multi-drug resistant 254 pneumococci was attributed to reduced within-host competition following 255 antimicrobial treatment, indicating that in the absence of treatment, susceptible 256 lineages outcompete resistant lineages ⁴³. In Malawi, as part of standard HIV clinical 257 management, PLHIV are put on daily co-trimoxazole prophylaxis ^{17, 18}. Consistent 258 259 with purifying selection and in agreement with previous studies ^{44, 45}, there was higher prevalence of co-trimoxazole resistant carriage isolates in PLHIV than HIV-260

261 uninfected participants. Considering that co-trimoxazole is a broad-spectrum antimicrobial and its resistance is associated with penicillin resistance^{45, 46}, it could 262 263 differentially alter the microbiota in the oropharyngeal and nasopharyngeal 264 compartments, resulting in stronger selection for multi-drug resistant pneumococci. 265 266 Consistent with their increased propensity for pneumococcal shedding, PLHIV 267 exhibited neutrophil-driven nasal inflammation. Neutrophil factors including NETs and MPO contribute to clearance of pneumococcal infection ^{47, 48}, but also promote 268 excessive inflammation ^{25, 49}. Host inflammation has been shown to drive 269 pneumococcal shedding ^{31, 32, 33 50}. In mice models, pneumococcal virulence factors, 270 such as pneumolysin and pneumococcal surface protein K (PspK), induce upper 271 respiratory tract (URT) inflammation resulting in pneumococcal shedding ^{32, 33, 51}. 272 Furthermore, uncontrolled inflammation has been shown to promote pneumococcal 273 persistence via nutrient provision arising from increased mucus secretion ^{52 53, 54}, and 274 through reduced mucocilliary clearance of pneumococci due to altered ciliary 275 beating ⁵⁵. Together, this suggests that uncontrolled nasal inflammation in PLHIV, 276 likely due to impaired nasal immunity ^{10, 56} or driven by altered URT microbiota, 277 perpetuates nasal inflammation leading to increased pneumococcal shedding, a 278 279 surrogate of transmission potential.

280

Despite the strengths of this study, including a comprehensive assessment of 281 carriage dynamics in a relevant population and setting, there are important 282 limitations. First, the standard microbiological assay used in this study were biased 283 towards isolating single isolates following culture, hence missing any potential 284 285 multiple serotype carriage episodes or pneumococci carried at low densities. Second, we did not directly measure pneumococcal transmission. Although pneumococcal 286 shedding is regarded as a surrogate for transmission potential ^{27, 28}, it is not clear 287 288 how often shed pneumococci result in successful transmission. However, this does not discount our suggestion that PLHIV on ART for more than 1 year contribute to 289

transmission of multi-drug resistant pneumococci, which is of public health

291 importance.

292

293 In conclusion, our study demonstrates that PLHIV on ART for more than 1 year could 294 be an important reservoir for transmission of multi-drug resistant *S. pneumoniae*. 295 This has potential to derail the success of the infant PCV programme and our fight 296 against antimicrobial resistance in high HIV prevalence and high pneumococcal carriage settings such as Malawi, especially now that there is an HIV test and treat 297 strategy ⁵⁷. Considering that PCV was shown to be efficacious against recurrent IPD 298 among PLHIV in Malawi⁵⁸, consideration should be given to re-evaluating the 299 provision of pneumococcal vaccination to this vulnerable adult population. 300

301

302 Methods

303 Study design and recruitment

We recruited asymptomatic PLHIV on ART for more than 1 year and HIV-uninfected 304 adults in Blantyre, Malawi. Participants were recruited on day 3 after screening and 305 then followed up on day 7, 14, 21 and 28 for the first month, and then every month 306 307 for 5 months. All participants were recruited from the ART clinics and Voluntary 308 Counselling and Testing (VCT) centres at Lighthouse-Queen Elizabeth Central 309 Hospital and Gateway Health Centre in Blantyre. Briefly, participants were screened for pneumococcal carriage, using WHO recommendations for nasopharyngeal 310 sampling and microbiological culture for pneumococcal detection ⁵⁹. Inclusion 311 criteria included confirmed pneumococcal carriage, in adults aged 18 to 45 years, 312 living with a child aged under-5-years and providing written informed consent. 313 Exclusion criteria included receiving antibiotics in the previous 4 weeks (apart from 314 co-trimoxazole prophylaxis as all PLHIV on ART receive daily co-trimoxazole 315 prophylaxis as per national guidelines ¹⁷), hospitalization for pneumonia in the 316 317 previous 4 weeks, having respiratory tract Kaposi's sarcoma or a terminal illness (e.g., metastatic malignancy, terminal AIDS). All PLHIV were on standardised ART regimen 318

according to Malawi Ministry of Health 2018 Clinical Management of HIV guidelines
 ⁶⁰.

321

322 The study was conducted in accordance with good clinical practice (GCP) guidelines

and the Declaration of Helsinki. Ethical approval was obtained from the College of

324 Medicine Research Ethics Committee (COMREC) (P.11/18/2532) and Liverpool School

of Tropical Medicine Research Ethics Committee (LSTMREC) (19-033).

326

327 Sample collection

Nasopharyngeal swabs were collected at all time points, and a peripheral blood sample was collected at recruitment (day 3) from PLHIV on ART for measuring CD4 count. In addition, respiratory secretions were collected at day 3, 21, and 28, using a modified polyvinyl acetate (PVA) facemask device ^{61, 62, 63}, direct coughing onto an agar plate (coughing), and inserting the participants clean index finger into the front of the nose (nose poking). Further details of these methods are discussed in the supplementary section.

335

Nasal cells were collected weekly (5 visits) by scraping the inferior turbinate using 336 337 nasal curette (Rhino-probe, Arlington Scientific, UK) as previously described ⁶⁴. Per individual and timepoint, two curettes were collected from each nostril. Briefly, the 338 four curette samples were immediately placed in a 15-ml falcon tube (Corning) 339 containing 8-ml of precooled transport media (RPMI-1640 [Thermo Fisher Scientific 340 Inc.) supplemented with 10% Fetal Bovine Saline [FBS], antibiotic/antimycotic [Sigma, 341 342 USA], L-glutamine, non-essential amino acids, HERPES buffer and sodium pyruvate (all from Gibco, USA)). 343

344

Nasal-lining fluid was collected weekly (5 visits) using a non-invasive method that
uses a synthetic absorptive matrix (SAM) strip (Hunts Development Ltd, UK). Briefly,
the nasosorption strip was advanced up the lumen of the nasal cavity and held inside

348 the nostril for up to three minutes until soaked. The strip was then removed and placed in a microcentrifuge tube for storage at -80°C until processing.

350

349

351 Microbiological culture and density quantification

Standard microbiologic culture was used to determine the presence of *S*. 352 353 pneumoniae from the nasal swab, nose poke swab, cough onto an agar plate and modified PVA facemask^{61, 62, 63}. For modified PVA facemask processing, four PVA 354 strips were removed from the mask using sterile technique and then dissolved in 355 10ml Todd Hewitt broth with 5% yeast (THY) and then plated. We identified S. 356 *pneumoniae* by their morphology and optochin sensitivity on a gentamicin-sheep 357 358 blood agar plate (SBG; 5% sheep blood agar, 5µL gentamicin/mL) after an overnight 359 incubation at 37 °C in 5% CO₂. The bile solubility test was used on isolates with no or intermediate (zone diameter < 14mm) optochin susceptibility. Plates showing no S. 360 pneumoniae growth were incubated for a further 24 hours before being reported as 361 negative. A single colony of confirmed pneumococcus was selected and grown on a 362 new SBG plate as before. Growth from this second plate was used for serotyping by 363 364 latex agglutination (ImmuLexTM 23-valent Pneumotest; Statens Serum Institute, Denmark). This kit allows for differential identification of each PCV13 vaccine 365 serotypes (VT) but not for differential identification of PCV13 non-vaccine serotypes 366 (NVT); NVT and non-typeable isolates were, therefore, reported as NVT. 367 Pneumococcal density was guantified using microbiological culture serial dilutions ⁶⁵ 368 on a gentamicin-sheep blood agar plate (SBG; 5% sheep blood agar, 5µL 369 370 gentamicin/mL) and results reported as colony forming units per millilitre (CFU/ml). 371

AMR profiling 372

Pure pneumococcal isolates were cultured on sheep blood agar without antibiotics 373 374 (SBA), using an overnight incubation at 37 °C in 5% CO₂. Growth from the SBA were 375 emulsified in normal saline to match 0.5 McFarland turbidity standard and plated on 376 sheep blood Muller Hinton agar plate without antibiotics (MHB) using a sterile cotton

377 swab. The antimicrobial susceptibility of pneumococcal isolates was assessed by the disk diffusion method (Oxoid, USA) for beta lactams antibiotic (oxacillin 1µg), 378 macrolide-lincosamide-streptogramin (MLS) antibiotic (erythromycin 15µg), 379 tetracycline antibiotic (tetracycline 30µg) and Trimethoprim/sulfamethoxazole (co-380 trimoxazole 1.25–23.75µg). 381 382 Beta lactams antibiotic susceptibility was confirmed by benzylpenicillin E-test 383 384 minimum inhibitory concentration (MIC). E-test MICs were determined by suspending colonies from an overnight culture (incubation at 37 °C in 5% CO2) on 385 386 SBA in saline, and the organism density was matched to a 0.5 McFarland turbidity standard. Using a sterile cotton swab, the organism suspension was plated onto 387 MHB. E-test strips were applied to the surface of the plates according to the 388 manufacturer's recommendations. Agar plates were incubated overnight at 37 °C in 389 390 5% CO2. The MIC was defined as the lowest concentration of drug where the zone edge intersected the E-test strip. 391

392

393 Interpretation of results followed European Committee on Antimicrobial

394 Susceptibility Testing (EUCAST) guidelines ⁶⁶. *Streptococcus pneumoniae* ATCC

49619 was used as quality control. Multidrug resistance (MDR) was defined as non-

396 susceptibility to agents in three or more above chemical classes of antibiotic.

397

398 Flow cytometry analysis

For immunophenotyping, nasal cells were dislodged from curettes by repeated
pipetting and stained with far-red fluorescent amine reactive dye (34973A, 1:1000)
from Invitrogen, and incubated for 15 minutes followed by the addition of a cocktail
of BV605 anti-human CD326 (9C4, 324224, 1:50), PerCp-Cy5.5 anti-human CD45
(HI30, 304028, 1:40), FITC anti-human CD66b (G10F5, 305104, 1:40), PE-Cy7 antihuman CD14 (M5E2, 301814, 1:40), APC-Cy7 anti-human CD3 (SK7, 344818, 1:40) and
PE-eFlour® 610 anti-human CD62L (DREG-56, 61062942, 1:40), all from Bio legend

406 (UK). Samples were acquired on LSR FORTESSA flow cytometer equipped with
407 FACSDIVA version 8.0.1 (BD Biosciences, UK) and analysed using Flowjo Version
408 10.8.1 (BD Biosciences, USA). Abundance of immune cells was normalised as immune
409 cell to epithelial cell ratio as previously reported ⁶⁷. All flow cytometry data are
410 available.

411

412	Neutrophil-extracellular traps (NETs) enzyme linked-immunosorbent assay
413	Nasosorption samples were eluted from stored nasosorption filters (Mucosal
414	Diagnostics, Hunt Development (UK) Ltd, Midhurst, UK) using 200μ L of elution buffer
415	(Millipore) by centrifugation at 1500g for 10 minutes as previously described ⁶⁸ . The
416	eluate was cleared by further centrifugation at 1595g for 10 minutes. The eluate was
417	then stored at -80°C until the day of the assay. The detection of NETs was performed
418	by combining two commercial ELISA kits; ROCHE cell death ELISA kit (Sigma Aldrich,
419	11920685001) and Human Elastase ELISA Kit (Hycult®Biotech, HK319). In-house
420	developed PMA NETs were serially diluted (1:2) and used as standards, while
421	nasosorption samples were diluted (1:4) using 1X dilution buffer from the Elastase
422	ELISA Kit (Hycult®Biotech, HK319).
423	

424 *Myeloperoxidase (MPO) enzyme linked-immunosorbent assay*

Myeloperoxidase (MPO) enzyme linked immunosorbent assay was performed on
eluted -80°C frozen nasal lining fluid samples as described in the manufacturer's user
guide (Invitrogen, UK, BMS2038INST).

428

429 *Statistical analysis*

430 Descriptive statistics are reported as numbers and proportions for categorical
431 variables, and median and confidence interval for continuous data. Categorical
432 variables were compared using χ2 test, and continuous variables were compared
433 using Mann-Whitney test. We fitted a univariate and multivariable regression model,
434 accounting for multiple sampling (generalized linear mixed model), covariables used

- 435 for each model are detailed in the supplementary section. All data analyses were
- 436 done in RStudio (Version 4.1.3, R Development Core Team, Vienna, Austria). Figures
- 437 and tables were produced in R (v4.1.3), RStudio (v2022.02. 2+485.pro2 Prairie Trillium
- 438 April 27, 2022), ggplot2 (v3.3.5), lme4 (v1.1-28), and gtsummary (v1.5.2)⁶⁹.
- 439 Statistical significance level was reported at a p value of <0.05.
- 440

441 Data availability

- 442 All data supporting these findings are available upon reasonable request.
- 443
- 444 References

445

Ganaie, F. *et al.* A new pneumococcal capsule type, 10D, is the 100th serotype
and has a large cps fragment from an oral streptococcus. *MBio* 11, e00937-00920
(2020).

449 2. Ganaie, F. *et al.* Structural, genetic, and serological elucidation of

450 Streptococcus pneumoniae serogroup 24 serotypes: Discovery of a new serotype,
451 24C, with a variable capsule structure. *Journal of Clinical Microbiology*, JCM. 00540-

452 00521 (2021).

3. O'Brien, K.L. *et al.* Burden of disease caused by Streptococcus pneumoniae in
children younger than 5 years: global estimates. *The Lancet* **374**, 893-902 (2009).

4. Weiser, J.N., Ferreira, D.M. & Paton, J.C. Streptococcus pneumoniae:
transmission, colonization and invasion. *Nat Rev Microbiol* 16, 355-367 (2018).

457 5. Waight, P.A. *et al.* Effect of the 13-valent pneumococcal conjugate vaccine on
458 invasive pneumococcal disease in England and Wales 4 years after its introduction:
459 an observational cohort study. *The Lancet Infectious Diseases* 15, 535-543 (2015).

460 6. Moore, M.R. *et al.* Effect of use of 13-valent pneumococcal conjugate vaccine
461 in children on invasive pneumococcal disease in children and adults in the USA:
462 analysis of multisite, population-based surveillance. *The Lancet Infectious Diseases*463 **15**, 301-309 (2015).

464 7. Swarthout, T.D. *et al.* High residual carriage of vaccine-serotype Streptococcus
465 pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. *Nature*466 *Communications* 11 (2020).

467 8. Usuf, E. *et al.* Pneumococcal carriage in rural Gambia prior to the introduction
468 of pneumococcal conjugate vaccine: a population-based survey. *Trop Med Int Health*469 20, 871-879 (2015).

Bar-Zeev, N. *et al.* Impact and effectiveness of 13-valent pneumococcal
conjugate vaccine on population incidence of vaccine and non-vaccine serotype
invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective

473 observational time-series and case-control studies. The Lancet Global Health 9, e989-474 e998 (2021). Glennie, S.J. et al. Defective Pneumococcal-Specific Th1 Responses in HIV-475 10. Infected Adults Precedes a Loss of Control of Pneumococcal Colonization. Clinical 476 Infectious Diseases 56, 291-299 (2013). 477 Heinsbroek, E. et al. Persisting high prevalence of pneumococcal carriage 478 11. 479 among HIV-infected adults receiving antiretroviral therapy in Malawi. AIDS 29, 1837-1844 (2015). 480 12. Thindwa, D. et al. Risk factors for pneumococcal carriage in adults living with 481 HIV on antiretroviral therapy in the infant pneumococcal vaccine era in Malawi. 482 medRxiv (2022). 483 Lehtinen, S. et al. Evolution of antibiotic resistance is linked to any genetic 484 13. mechanism affecting bacterial duration of carriage. *Proceedings of the National* 485 486 Academy of Sciences 114, 1075-1080 (2017). Tonkin-Hill, G. et al. Pneumococcal within-host diversity during colonisation, 487 14. transmission and treatment. Cold Spring Harbor Laboratory; 2022. 488 Chaguza, C. et al. Recombination in Streptococcus pneumoniae lineages 489 15. 490 increase with carriage duration and size of the polysaccharide capsule. *MBio* 7, 491 e01053-01016 (2016). Organization, W.H. World Health Organization. Global antimicrobial resistance 492 16. and use surveillance system (GLASS) report. (2021). 493 494 Organization, W.H. Guidelines on post-exposure prophylaxis for HIV and the 17. 495 use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: December 496 497 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral 498 drugs for treating and preventing HIV infection. World Health Organization, 2014. Laurens, M.B. et al. Revisiting Co-Trimoxazole Prophylaxis for African Adults in 499 18. The Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial. *Clinical* 500 501 Infectious Diseases (2021). Ho, A. et al. Epidemiology of Severe Acute Respiratory Illness and Risk Factors 502 19. for Influenza Infection and Clinical Severity among Adults in Malawi, 2011–2013. The 503 American Journal of Tropical Medicine and Hygiene 99, 772-779 (2018). 504 505 20. Ho, A. et al. Impact of Human Immunodeficiency Virus on the Burden and Severity of Influenza Illness in Malawian Adults: A Prospective Cohort and Parallel 506 507 Case-Control Study. Clinical Infectious Diseases 66, 865-876 (2018). Manna, S. et al. Synergism and Antagonism of Bacterial-Viral Coinfection in 508 21. 509 the Upper Respiratory Tract. mSphere 7, e0098421 (2022). 510 22. Karppinen, S. et al. Acquisition and Transmission of Streptococcus pneumoniae Are Facilitated during Rhinovirus Infection in Families with Children. Am 511 J Respir Crit Care Med 196, 1172-1180 (2017). 512 Peterson, I. et al. Respiratory Virus-Associated Severe Acute Respiratory Illness 513 23. and Viral Clustering in Malawian Children in a Setting With a High Prevalence of HIV 514

515 Infection, Malaria, and Malnutrition. Journal of Infectious Diseases 214, 1700-1711 516 (2016). Zawłocka, E., Czajkowska, M., Wrotek, A. & Jackowska, T. P388 RSV and 517 24. influenza co-infections in children in three consecutive influenza epidemic seasons. 518 Archives of Disease in Childhood 104, A311 (2019). 519 520 25. Jochems, S.P. et al. Inflammation induced by influenza virus impairs human innate immune control of pneumococcus. Nat Immunol 19, 1299-1308 (2018). 521 Murakami, D. et al. Exposure to Cigarette Smoke Enhances Pneumococcal 522 26. Transmission Among Littermates in an Infant Mouse Model. Front Cell Infect 523 524 Microbiol 11, 651495 (2021). Connor, V. et al. Hands are vehicles for transmission of Streptococcus 525 27. pneumoniae in novel controlled human infection study. *European Respiratory Journal* 526 **52**, 1800599 (2018). 527 528 28. Smith-Vaughan, H., Crichton, F., Beissbarth, J., Morris, P.S. & Leach, A.J. Survival of pneumococcus on hands and fomites. BMC Research Notes 1, 112 (2008). 529 Wolter, N. et al. High Nasopharyngeal Pneumococcal Density, Increased by 530 29. Viral Coinfection, Is Associated With Invasive Pneumococcal Pneumonia. The Journal 531 of Infectious Diseases 210, 1649-1657 (2014). 532 Carr, O.J.J. et al. Nasopharyngeal Pneumococcal Colonization Density Is 533 30. Associated With Severe Pneumonia in Young Children in the Lao People's 534 Democratic Republic. The Journal of Infectious Diseases 225, 1266-1273 (2021). 535 Zangari, T., Ortigoza, M.B., Lokken-Toyli, K.L. & Weiser, J.N. Type I Interferon 536 31. Signaling Is a Common Factor Driving Streptococcus pneumoniae and Influenza A 537 Virus Shedding and Transmission. *mBio* 12 (2021). 538 Zafar, M.A. et al. Identification of Pneumococcal Factors Affecting 539 32. Pneumococcal Shedding Shows that the dlt Locus Promotes Inflammation and 540 541 Transmission. *mBio* **10** (2019). Zafar, M.A., Wang, Y., Hamaguchi, S. & Weiser, J.N. Host-to-Host Transmission 542 33. 543 of Streptococcus pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. Cell 544 Host Microbe 21, 73-83 (2017). Ekstedt, S., Larsson, O., Kumlien Georén, S. & Cardell, L.O. CD16(high) 545 34. CD62L(dim) neutrophils induce nerve-mediated airway hyperreactivity. *Clin Exp* 546 547 *Allergy* **50**, 756-759 (2020). Ivetic, A., Hoskins Green, H.L. & Hart, S.J. L-selectin: A Major Regulator of 548 35. Leukocyte Adhesion, Migration and Signaling. Front Immunol 10, 1068 (2019). 549 Hodges, R.G. & Macleod, C.M. Epidemic Pneumeeoccal Pneumonia. II. The 550 36. Influence of Population Characteristics and Environment. American journal of hygiene 551 552 **44**, 193-206 (1946). Hohwy, J., Reinholdt, J. & Kilian, M. Population dynamics of Streptococcus 553 37. mitis in its natural habitat. Infection and immunity 69, 6055-6063 (2001). 554 555 38. Jensen, A., Valdórsson, O., Frimodt-Møller, N., Hollingshead, S. & Kilian, M. Commensal streptococci serve as a reservoir for β -lactam resistance genes in 556

557 Streptococcus pneumoniae. *Antimicrobial agents and chemotherapy* **59**, 3529-3540

. 558 (2015).

39. Ready, D., Bedi, R., Spratt, D., Mullany, P. & Wilson, M. Prevalence, proportions,
and identities of antibiotic-resistant bacteria in the oral microflora of healthy

children. *Microbial Drug Resistance* **9**, 367-372 (2003).

Kalizang'oma, A. *et al.* Streptococcus pneumoniae serotypes that frequently
colonise the human nasopharynx are common recipients of penicillin-binding protein
gene fragments from Streptococcus mitis. *Microb Genom* 7 (2021).

Jensen, A., Valdórsson, O., Frimodt-Møller, N., Hollingshead, S. & Kilian, M.
Commensal streptococci serve as a reservoir for β-lactam resistance genes in
Streptococcus programming Antimicroh Agents Chamather **50**, 2520, 2540 (2015).

567 Streptococcus pneumoniae. *Antimicrob Agents Chemother* 59, 3529-3540 (2015).
568 42. Sauerbier, J., Maurer, P., Rieger, M. & Hakenbeck, R. Streptococcus

569 pneumoniae R6 interspecies transformation: genetic analysis of penicillin resistance
570 determinants and genome-wide recombination events. *Mol Microbiol* 86, 692-706
571 (2012).

- 572 43. Tonkin-Hill, G. *et al.* Pneumococcal within-host diversity during colonization,
 573 transmission and treatment. *Nature Microbiology* (2022).
- 44. Pemba, L. *et al.* Impact of cotrimoxazole on non-susceptibility to antibiotics in
 Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in
 South Africa. *Journal of Infection* 56, 171-178 (2008).
- 577 45. Seid, M. *et al.* Does cotrimoxazole prophylaxis in HIV patients increase the
 578 drug resistance of pneumococci? A comparative cross-sectional study in southern
 579 Ethiopia. *PLOS ONE* 15, e0243054 (2020).
- 46. Liñares, J., Perez, J., Garau, J., Murgui, L. & Martin, R. Comparative
 susceptibilities of penicillin-resistant pneumococci to co-trimoxazole, vancomycin,
 rifampicin and fourteen β-lactam antibiotics. *Journal of Antimicrobial Chemotherapy*
- **13**, 353-359 (1984).
- 47. Monteith, A.J., Miller, J.M., Maxwell, C.N., Chazin, W.J. & Skaar, E.P. Neutrophil
 extracellular traps enhance macrophage killing of bacterial pathogens. *Sci Adv* 7,
 eabj2101 (2021).
- 587 48. Nikolaou, E. *et al.* Experimental Human Challenge Defines Distinct
- 588 Pneumococcal Kinetic Profiles and Mucosal Responses between Colonized and Non-589 Colonized Adults. *mBio* **12** (2021).

590 49. Dong, Y. *et al.* TLR4 regulates ROS and autophagy to control neutrophil

- 591 extracellular traps formation against Streptococcus pneumoniae in acute otitis media.
 592 *Pediatr Res* 89, 785-794 (2021).
- 593 50. Weiser, J.N., Ferreira, D.M. & Paton, J.C. Streptococcus pneumoniae:
 594 transmission, colonization and invasion. *Nature Reviews Microbiology* 16, 355-367
- 595 (2018).
- 596 51. Sakatani, H. *et al.* A Novel Pneumococcal Surface Protein K of
- 597 Nonencapsulated Streptococcus pneumoniae Promotes Transmission among
- 598 Littermates in an Infant Mouse Model with Influenza A Virus Coinfection. *Infect*
- 599 *Immun* **90**, e0062221 (2022).

600 52. Siegel, S.J., Roche, A.M. & Weiser, J.N. Influenza promotes pneumococcal 601 growth during coinfection by providing host sialylated substrates as a nutrient source. Cell Host Microbe 16, 55-67 (2014). 602

Hammond, A.J. et al. Neuraminidase B controls neuraminidase A-dependent 603 53. mucus production and evasion. *PLoS Pathog* 17, e1009158 (2021). 604

605 54. Wu, M. et al. Epithelium-derived IL17A Promotes Cigarette Smoke-induced Inflammation and Mucus Hyperproduction. Am J Respir Cell Mol Biol 65, 581-592 606 607 (2021).

55. Sender, V., Hentrich, K. & Henriques-Normark, B. Virus-Induced Changes of 608 the Respiratory Tract Environment Promote Secondary Infections With Streptococcus 609 pneumoniae. Front Cell Infect Microbiol 11, 643326 (2021). 610

Jambo, K.C. et al. Bronchoalveolar CD4+ T cell responses to respiratory 611 56. antigens are impaired in HIV-infected adults. Thorax 66, 375-382 (2011). 612

- 613 57. Ministry of Health and Population, M. Malawi Clinical HIV Guidelines. In: Ministry of Health and Population, M., editor.; 2018. 614
- French, N. et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-615 58. infected adults. N Engl J Med 362, 812-822 (2010). 616
- 617 Satzke, C. et al. Standard method for detecting upper respiratory carriage of 59.
- Streptococcus pneumoniae: Updated recommendations from the World Health 618 Organization Pneumococcal Carriage Working Group. Vaccine 32, 165-179 (2013). 619
- Ministry of Health, M. Clinical management of HIV in Children and Adults; 620 60. 2011. 621
- Al-Taie, A. et al. 3-D printed polyvinyl alcohol matrix for detection of airborne 622 61. pathogens in respiratory bacterial infections. *Microbiological research* 241, 126587 623 624 (2020).
- 625 62. Williams, C.M. et al. Exhaled SARS-CoV-2 quantified by face-mask sampling in hospitalised patients with COVID-19. Journal of Infection 82, 253-259 (2021). 626
- Hu, B. Recent advances in facemask devices for in vivo sampling of human 627 63. 628 exhaled breath aerosols and inhalable environmental exposures. TrAC Trends in Analytical Chemistry, 116600 (2022). 629
- Jochems, S.P. et al. Novel analysis of immune cells from nasal microbiopsy 64. 630 demonstrates reliable, reproducible data for immune populations, and superior 631 632 cytokine detection compared to nasal wash. *PloS one* 12, e0169805 (2017).
- 65. Miles, A.A., Misra, S.S. & Irwin, J.O. The estimation of the bactericidal power of 633 634 the blood. *Epidemiology and Infection* 38, 732-749 (1938).
- Testing, T.E.C.o.A.S. Breakpoint tables for interpretation of MICs and zone 635 66. 636 diameters; 2022.
- Roukens, A.H.E. et al. Prolonged activation of nasal immune cell populations 637 67. and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses 638
- following COVID-19. Nature Immunology 23, 23-32 (2022). 639
- 640 68. Morton, B. et al. Distinct clinical and immunological profiles of patients with
- 641 evidence of SARS-CoV-2 infection in sub-Saharan Africa. Nat Commun 12, 3554 642 (2021).

643 69. Larmarange, D.D.S.a.K.W.a.M.C.a.J.A.L.a.J. Reproducible Summary Tables with 644 the gtsummary Package. *The R Journal* **13**, 570-580 (2021).

645 646

647 Acknowledgements

The authors thank all study participants, and the staff of the Queen Elizabeth Central 648 Hospital (QECH) Lighthouse and Gateway Clinic, for their support and co-operation 649 during the study. This work was supported by the National Institute for Health 650 Research (NIHR) [16/136/46]. KCJ is supported by an MRC African Research Leader 651 award [MR/T008822/1]. RSH is a NIHR senior investigator. The views expressed in this 652 653 publication are those of the authors and not necessarily those of the NIHR or the UK government. A Wellcome Strategic award number 206545/Z/17/Z supports MLW. 654 The funders were not involved in the design of the study; in the collection, analysis, 655 and interpretation of the data; and in writing the manuscript. The findings and 656 conclusions in this report are those of the authors and do not necessarily represent 657 658 the official position of the funders.

659

660 Author contributions

- 661 The author contributions were as follows: Methodology: K.C.J., R.S.H. and N.F.
- 662 Investigation: L.S., J.P., N.M., N.K., T.N., A.K., M.K., and G.S. Data analysis: K.C.J., L.S.,
- and J.P. Interpretation: K.C.J., L.S., J.P., R.S.H., B.K.A, T.D.S., and N.F. Data curation: L.S.
- and J.P. Project administration: N.M., N.K. and K.C.J. Sample collection: A.K., M.K., and
- 665 G.S. Writing: L.S., J.P., and K.C.J. Conceptualisation and supervision: K.C.J., R.S.H., B.K.A,
- and N.F. All authors read and approved the final manuscript.
- 667
- 668 *Corresponding author*
- 669 Correspondence to Kondwani C. Jambo
- 670
- 671 Competing interests
- The authors declare no competing interests

673 Figures







674

675

676

Figure 1. Recruitment flow diagram and study design. A) Flow diagram showing the
 number of adults and pneumococcal samples included in the analysis among PLHIV
 on ART and HIV uninfected participants. B) Sampling strategy, showing longitudinal
 following of study participants and sample callection projects

680 follow up of study participants and sample collection points.





682

Figure 2. Overall (VT+NVT) pneumococcal swab positivity among PLHIV and HIV-683

uninfected adults. A) HIV-stratified pneumococcal swab positivity. B) HIV and 684

serogroup stratified pneumococcal swab positivity by different nasopharyngeal 685

sampling visits. C) HIV and serogroup stratified pneumococcal swab positivity. D) 686 HIV-stratified proportion of PCV13 serotypes. The denominator for each serotype is 687

the total PCV13 serotypes in each group. Black vertical lines represent 95% 688

confidence intervals. Data were analysed using Chi-square test (HIV-uninfected: 689

690 n=35, PLHIV: n=55). Source data are provided as a Source Data file. PCV13,

pneumococcal conjugated vaccine 13; ART, antiretroviral therapy; NVT non-PCV13 691

- serotype; VT, PCV13 serotypes 692
- 693
- 694





participants. Log median carriage density stratified by HIV status for 5 months study

follow-up time. For all boxplots, box boundaries correspond to 25th and 75th

percentiles; whiskers extend to a maximum of 1.5x the inter-quartile range, with

values outside the box and whiskers being outliers. Data were analysed using

Wilcoxon test (HIV-uninfected: n=35, PLHIV: n=55). Source data are provided as a

Source Data file. ART, antiretroviral therapy; CFU, colony forming units







Figure 4. Pneumococcal shedding among PLHIV and HIV-uninfected adults. 718

Pneumococcal shedding was defined as presence of viable pneumococci following 719 microbiological culture of samples collected through nose poking (mechanical) and 720 coughing or facemask sampling (aerosol). A) Overall pneumococcal shedding 721 positivity stratified by HIV status. B). Overall pneumococcal shedding positivity 722 stratified by HIV status and serogroup. C). Overall pneumococcal shedding positivity 723 stratified by HIV status and PCV13 serotypes, the denominator for each serotype is 724 725 the total PCV13 serotypes in each group. D). Pneumococcal mechanical shedding positivity stratified by HIV status E). Pneumococcal aerosol shedding positivity 726 stratified by HIV status. The vertical bars represent median and horizontal lines 727 represent confidence intervals (CI) (black lines). Data were analysed using Chi-square 728 729 test (HIV-uninfected: n=23, PLHIV: n=61). Source data are provided as a Source Data file. ART, antiretroviral therapy 730 731

- 732
- 733
- 734 735
- 736

medRxiv preprint doi: https://doi.org/10.1101/2022.10.28.22281638; this version posted October 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



737

Figure 5. Nasal immune responses in adults with or without HIV. Immune cell 738

profiling was done on nasal curette-collected mucosa cells using flow cytometry-739

based immunophenotyping, while concentration of NETs and MPO were measured in 740

nasal lining fluid using ELISAs, in HIV-uninfected adults and PLHIV. Samples were 741

collected weekly for 4 weeks in all participants. A) Representative flow cytometry plot 742

- from an HIV-uninfected participant showing a gating strategy for the identification of 743
- 744 immune cells in the nasal mucosa. B-D) Plots showing abundance of immune cell

745 746 747 748 749 750 751 752 753	subsets at all time points in the nasal mucosa of HIV-uninfected and PLHIV. Data was normalised as immune cell to epithelial cell ratio. E) Median fluorescence Intensity (MFI) of CD62L expression on neutrophils between HIV-uninfected and PLHIV at all time points. For all boxplots, box boundaries correspond to 25 th and 75 th percentiles; whiskers extend to a maximum of 1.5x the inter-quartile range, with values outside the box and whiskers being outliers. Data were analysed using Wilcoxon test (HIV- uninfected: n=10, PLHIV: n=9). Source data are provided as a Source Data file. ART, antiretroviral therapy
754	
755	
756	
757	
758	
759	
760	
761	
762	
763	
764	
765	
766	
767	
768	
769	
770	
771	
772	
773	
774	
775	
776	

777 Tables

778 Table 1

Table 1.	Baseline characteristics		
Characteristic	HIV- , N = 35 ¹	PLHIV , N = 55 ¹	p-value ²
Sex			0.7
Female	25 (71%)	41 (75%)	
Male	10 (29%)	14 (25%)	
Age group			0.049
18-25	12 (34%)	10 (18%)	
26-35	16 (46%)	21 (38%)	
36-45	7 (20%)	24 (44%)	
Number of U5 children per household			0.7
1	26 (74%)	45 (82%)	
2	8 (23%)	9 (16%)	
3	1 (2.9%)	1 (1.8%)	
Socioeconomic status ³			0.005
Median (IQR)	6.00 (3.50, 7.50)	4.00 (2.00, 5.00)	
CD4 count (Cells/µl)			<0.001
Median (IQR)	760 (652, 927)	514 (332, 750)	
ART duration (Years)			
Median (IQR)	NA (NA, NA)	5.8 (3.4, 11.3)	
HIV viral load (Copies/ml) ⁴		,	
Median (IQR)	NA (NA, NA)	39 (39, 18,928)	
· · ·			

¹ n (%)

² Pearson's Chi-squared test; Fisher's exact test; Wilcoxon rank sum test

³ Socioeconomic status score based a possession index which is calculated as a sum of positive responses for household ownership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television ⁴ i.e. Only 10 PLHIV on ART>1yr had a detectable Viral load

779

780

781

- 783
- 784
- 785
- 786
- 787
- 788

- 790
- 791

792 Table 2

Table 2. Pneumococcal density <=2010CFU/ml vs Pneumococcal density >2010CFU/ml

		Univariate			Multivariable		
Characteristic	OR ⁷	95% Cl¹	p-value	OR ¹	95% Cl¹	p-value	
HIV status							
HIV-		—		_			
PLHIV	1.55	1.04, 2.31	0.030	1.62	1.06, 2.49	0.027	
Sex							
Female		—		—	—		
Male	0.92	0.59, 1.43	0.7	0.85	0.53, 1.36	0.5	
Age group							
18-25		—		—			
26-35	0.84	0.50, 1.40	0.5	0.69	0.40, 1.20	0.2	
36-45	0.94	0.56, 1.59	0.8	0.69	0.38, 1.25	0.2	
Season							
Cooldry		—		—	—		
Hotwet	0.82	0.55, 1.23	0.3	0.78	0.52, 1.17	0.2	
Socioeconomic status ²							
Medium/high ses (> 3)							
Low ses (<= 3)	1.21	0.81, 1.80	0.4	1.19	0.78, 1.83	0.4	

¹ OR = Odds Ratio, CI = Confidence Interval

² Socioeconomic status score based a possession index which is calculated as a sum of positive responses for household ownership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. Middle and high SES were combined

-

808 Table 3

Table 3. Factor	s associated wit	th pneumod	coccal she	edding	J		
		Univariate				Multivariable	
Characteristic	\mathbf{OR}^{7}	95% Cl ¹	p-value	OR ¹	95% Cl ¹	p-value	
HIV status							
HIV-	_			_	_		
PLHIV	2.24	1.22, 4.13	0.010	2.44	1.04, 5.69	0.039	
Sex							
Female	_	_		—	_		
Male	0.89	0.52, 1.52	0.7	1.24	0.61, 2.53	0.6	
Age group							
18-25	_			_	_		
26-35	1.85	0.90, 3.80	0.093	1.62	0.64, 4.13	0.3	
36-45	2.13	1.01, 4.46	0.046	2.01	0.76, 5.34	0.2	
Pernasal swab carriage density (CFU/ml)						
Low density <=2010	_						
Medium/High density >2010	3.42	1.75, 6.67	<0.001	3.37	1.56, 7.29	0.002	
Season							
Cooldry	_	_		—	_		
Hotwet	1.42	0.83, 2.43	0.2	1.18	0.58, 2.39	0.6	
Socioeconomic status ²							
Medium/high ses (> 3)		_		_	_		
Low ses (<= 3)	0.59	0.34, 1.00	0.052	0.64	0.31, 1.31	0.2	
		1			,		

¹ OR = Odds Ratio, CI = Confidence Interval

² Socioeconomic status score based a possession index which is calculated as a sum of positive responses for household ownership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. Middle and high SES were combined

810 * Pneumococcal shedding was defined as presence of viable pneumococci following microbiological

culture of samples collected through nose poking (mechanical) and coughing or facemask sampling(aerosol).

Table 4

Table 4. Baseline	pneumococcal c	arriage isolates a	ntibiogram
Characteristic	HIV- , N = 35 ¹	PLHIV , N = 57 ¹	p-value ²
Cotrimoxazole			0.002
Susceptible	8 (24%)	1 (2.0%)	
non-susceptible	26 (76%)	50 (98%)	
Oxacillin			0.5
Susceptible	15 (43%)	26 (51%)	
non-susceptible	20 (57%)	25 (49%)	
Tetracycline			0.2
Susceptible	16 (47%)	32 (63%)	
non-susceptible	18 (53%)	19 (37%)	
Erythromycin			0.058
Susceptible	21 (62%)	41 (80%)	
non-susceptible	13 (38%)	10 (20%)	
MDR ³			0.5
non MDR	26 (76%)	42 (82%)	
MDR ³	8 (24%)	9 (18%)	
1 - (0/)	. ,	. /	

⁷ n (%)

² Fisher's exact test; Pearson's Chi-squared test

³ i.e. Oxacillin is excluded from MDR definition

Table 5 844

	Table 5. P	neumocc	occal shedding i	solates	antibiogra	m among PLHI\	/	
	Aerosol shedding vs Nasopharyngeal carriage				Mechanical shedding vs Nasopharyngeal carriage			
	Characteristic	Aerosol shedding, $N = 44^{7}$	Nasopharyngeal carriage. $N = 44^{7}$	p- value ²	Mechanical shedding, $N = 50^{7}$	Nasopharyngeal carriage, $N = 50^{10}$	p- value	
	Tetracycline	27 (61%)	11 (26%)	< 0.001	16 (32%)	15 (30%)	0.8	
	Erythromycin	19 (43%)	12 (28%)	0.14	14 (28%)	16 (32%)	0.7	
	Cotrimoxazole	41 (93%)	41 (95%)	>0.9	47 (94%)	46 (92%)	>0.9	
	Benzylpenicillin ³	27 (61%)	14 (32%)	0.010	19 (38%)	14 (28%)	0.4	
	MDR	28 (64%)	13 (30%)	0.001	15 (30%)	15 (30%)	>0.9	
	⁷ n (%) ² Pearson's Chi-squa ³ i.e. Minimum inhibit	ared test; Fis	her's exact test					
845		lory concent	ration					
846								
847								
848								
849								
850								
851								
852								
853								
854								
855								
856								
857								
858								
859								
860								
861								